YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

HPLC Determination and Pharmacokinetic Profile of Warfarin in Korean Subjects

와파린의 HPLC 분석법 및 한국인에서의 약동학적 특징

  • Bae, Jung-Woo (Lab. of Pharmacology, College of Pharmacy, Sungkyunkwan University) ;
  • Kim, Hyun-Kyung (Lab. of Pharmacology, College of Pharmacy, Sungkyunkwan University) ;
  • Yang, Sang-In (Lab. of Pharmacology, College of Pharmacy, Sungkyunkwan University) ;
  • Kim, Ji-Hong (Lab. of Pharmacology, College of Pharmacy, Sungkyunkwan University) ;
  • Kim, Kyung-Hye (Lab. of Pharmacology, College of Pharmacy, Sungkyunkwan University) ;
  • Jang, Choon-Gon (Lab. of Pharmacology, College of Pharmacy, Sungkyunkwan University) ;
  • Park, Young-Seo (Department of Pediatrics , University of Ulsan College of Medicine, Asan Medical Center) ;
  • Sohn, Uy-Dong (College of Pharmacy, Chung-Ang University) ;
  • Published : 2005.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Warfarin is a widely used oral anticoagulant agent used to treat thromboembolic disease. The purpose of this study was to develop the efficient assay method of warfarin sodium i n human plasma and to assess the pharmacokinetic profile of the warfarin in healthy Korean volunteers. The pharmacokinetics of warfarin administered orally was evaluated after a dose of 10 mg. Warfarin in plasma was assayed using a specific HPLC method with UV absorbance at 304 nm. AUC was 46.33${\pm}9.95{\mu}g/ml.hr$, $C_{max}$ $1.22{\pm}0.22{\mu}g/ml, $T_{max}$$2.50{\pm}1.41$ hr and half-life $43.49{\pm}4.33$ hr. $T_{max}$ was slightly shorter than that in Caucasian (3~9 hr), whereas the half-life was longer than that in Caucasian (10~45 hr, mean: 36 hr). These results suggest that warfarin may have a longer duration in Korean than in Caucasian.

Keywords

References

  1. Dollery, C., The Therapeutic Drugs. 2nd ed. Churchill Livingstone, London, p. W1 (1999)
  2. O'reilly, R. A., Aggeler, P. M. and Leong, L. S. : Studies on the coumarin anticoagulant drugs: The pharmacodynamics of warfarin in man. J. Clin. Invest. 42, 1542 (1963) https://doi.org/10.1172/JCI104839
  3. Breckenridge, A. and Orme, M. : Measurement of plasma warfarin concentration in clinical practice. In Biological Effects of Drugs in Relation to their Plasma Concentrations. Mavmillan, London, 145 (1973)
  4. O'Reilly, R. A. : Studies on the optical enantiomorphs of warfarin in man. Clin. Pharmacol. Ther. 16, 348 (1974) https://doi.org/10.1002/cpt1974162348
  5. Hewick, D. S. and McEwen, J. : Plasma half-lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in man. J. Pharm. Pharmacol. 25, 458 (1973) https://doi.org/10.1111/j.2042-7158.1973.tb09133.x
  6. Scott, A. K., Park, B. K. and Breckenridge, A. M. : Interaction between warfarin and propranolol. Br. J. Clin. Pharmacol. 17, 559 (1984) https://doi.org/10.1111/j.1365-2125.1984.tb02390.x
  7. O'Reilly, R. A. : The binding of sodium warfarin to plasma albumin and its displacement by phenylbutazone. Ann. N. Y. Acad. Sci. 226, 293 (1973) https://doi.org/10.1111/j.1749-6632.1973.tb20491.x
  8. Hignite, C., Uetrecht, J., Tschanz, C. and Azarnoff, P. : Kinetics of R and S warfarin enantiomers. Clin. Pharmacol. Ther. 28, 99 (1980) https://doi.org/10.1038/clpt.1980.137
  9. Loun, B. and Hage, D. S. : Chiral separation mechanisms in protein-based HPLC columns. 1. Thermodynamic studies of (R)- and (S)-warfarin binding to immobilized human serum albumin. Anal. Chem. 66, 3814 (1994) https://doi.org/10.1021/ac00093a043
  10. King, S. Y., Joslin, M. A., Taudibaugh, K, Pieniaszek, H.J. and Benedek, I. H. : Does-dependent pharmacokinetics of warfarin in healthy volunteers. Pharm. Res. 12, 1874 (1995) https://doi.org/10.1023/A:1016223418652
  11. Ring, P. R. and Bostick, J. M. : Validation of a method for the determination of (R)-warfarin and (S)-warfarin in human plasma using LC with UV detection. J. Pharm. Biomed. Anal. 22, 573 (2000) https://doi.org/10.1016/S0731-7085(00)00232-6
  12. Robertson, P. Jr., Hellriegel, E. T., Arora, S. and Nelson, M. : Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers. J. Clin. Pharmacol. 42, 205 (2002) https://doi.org/10.1177/00912700222011120
  13. Boppana, V. K., Schaefer, W. H. and Cyronak, M. J. : High-performance liquid-chromatographic determination of warfarin enantiomers in plasma with automated on-line sample enrichment. J. Biochem. Biophys. Methods 54, 315 (2002) https://doi.org/10.1016/S0165-022X(02)00122-7
  14. Shearer, M. J. : High-performance liquid chromatography of K vitamins and their antagonists. Adv. Chromatogr. 21, 243 (1983)
  15. Naidong, W. and Lee, J. W. : Development and validation of a high performance liquid chromatographic method for the quantitation of warfarin enantiomers in human plasma. J. Pharm. Biomed. Anal. 11, 785 (1993) https://doi.org/10.1016/0731-7085(93)80060-E
  16. Moore, E. S. : Liquid chromatographic determination of coumarin anticoagulants in tablets: collaborative study. J. Assoc. Off. Anal. Chem. 70, 834 (1987)
  17. Haber, L. T., Maier, A., Gentry, P. R., Clewell, H. J. and Dourson, M. L. : Genetic polymorphisms in assessing interindividual variability in delivered dose. Regul. Toxicol. Pharmacol. 35, 177 (2002) https://doi.org/10.1006/rtph.2001.1517
  18. Takahashi, H., Wilkinson, G. R., Caraco, Y., Muszkat, M., Kim, R. B., Kashima, T., Kimura, S. and Echizen, H. : Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin. Pharmacol. Ther. 73, 253 (2003) https://doi.org/10.1067/mcp.2003.26a
  19. Choonara, I. A., Cholerton, S., Haynes, B. P., Breckenridge, A. M. and Park, B. K. : Stereoselective interaction between the R enantiomer of warfarin and cimetidine. Br. J. Clin. Pharmacol, 21. 271 (1986) https://doi.org/10.1111/j.1365-2125.1986.tb05190.x
  20. Black, D.J., Kunze, K. L., Wienkers L. C., Gidal, B. E., Seaton, T. L., McDonnell, N. D., Evans, J. S., Bauwens, J. E. and Trager, W. F. : Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab. Dispos. 24, 422 (1996)
  21. Rettie, A. E., Korzekwa, K. R., Kunze, K. L., Lawrence, R. F., Eddy, A. C., Aoyama, T., Gelboin, H. V., Gonzalez, F. J. and Trager, W. F. : Hydroxylation of warfarin by human cDNA expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 5, 54 (1992) https://doi.org/10.1021/tx00025a009
  22. Takahashi, H. and Echizen, H. : Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J. 3, 202 (2003) https://doi.org/10.1038/sj.tpj.6500144
  23. Linder, M. W., Looney, S., Adams, J. E. 3rd., Johnson, N., Antonino-Green, D., Lacefield, N., Bukaveckas, B. L. and Valdes, R. Jr. : Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J. Thromb. Thrombolysis 14, 227 (2002) https://doi.org/10.1023/A:1025052827305
  24. Aithal, G. P., Day, C. P., Kesteven, P. J. and Daly, A. K. : Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 353, 717 (1999) https://doi.org/10.1016/S0140-6736(99)02059-0
  25. Daly, A. K. and King, B. P. : Pharmacogenetics of oral anticoagulants. Pharmacogenetics 13, 247 (2003) https://doi.org/10.1097/00008571-200301000-00002